New insights into the immunopathology of FA have led to development of cautious use of controlled exposure to food allergens through allergen immunotherapy and emerging use of monoclonal antibody therapy to interfere with the synthesis of immunoglobulin E (IgE). The expert faculty will contextualize the mechanisms and available clinical trial data related to the use of biologic agents in FA as monotherapy and as adjunct therapy to allergen immunotherapy.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/FUVJYI
- Start Date: 2024-04-30 05:00:00
- End Date: 2024-04-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Genentech (Any division) - Amount: 109850.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest